CVSI
CV Sciences, Inc.
Overview
CV Sciences manufactures and distributes hemp-extract CBD products, plant-based foods, and supplement softgels under brands including +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox.
CV Sciences, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $4.7M market cap.
Most recent reported earnings: Q1 FY2026 (May 14, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-141 Q&A exchange
- Q2 FY2025Earnings2025-08-201 Q&A exchange
- Q1 FY2025Earnings2025-05-141 Q&A exchange
- Q4 FY2024Earnings2025-03-271 Q&A exchange
- Q3 FY2024Earnings2024-11-141 Q&A exchange
- Q2 FY2024Earnings2024-08-13
- Q1 FY2024Earnings2024-05-141 Q&A exchange
- Q4 FY2023Earnings2024-03-28
- Q3 FY2023Earnings2023-11-14
- Q2 FY2023Earnings2023-08-14
- Q1 FY2023Earnings2023-05-151 Q&A exchange
- Q4 FY2022Earnings2023-03-29
- Q3 FY2022Earnings2022-11-14
- Q2 FY2022Earnings2022-08-15
- Q1 FY2022Earnings2022-05-164 Q&A exchanges
- Q4 FY2021Earnings2022-03-31
- Q3 FY2021Earnings2021-11-157 Q&A exchanges
- Q2 FY2021Earnings2021-08-127 Q&A exchanges
- Q1 FY2021Earnings2021-05-1310 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-14EPS$-0.00 vs ——Rev— vs ——EODHD
- Q4 FY20252026-03-25EPS$-0.00 vs ——Rev$3.3M vs ——EODHD
- Q3 FY20252025-11-12EPS$-0.00 vs $0.00—Rev$3.3M vs ——EODHD
- Q2 FY20252025-08-12EPS$-0.00 vs $0.00—Rev$3.6M vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.00 vs ——Rev$3.6M vs ——EODHD
- Q4 FY20242025-03-25EPS$-0.00 vs ——Rev$3.9M vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.00 vs ——Rev$3.9M vs ——EODHD
- Q2 FY20242024-08-12EPS$-0.00 vs ——Rev$4.0M vs ——EODHD
- Q1 FY20242024-05-13EPS$-0.00 vs ——Rev$4.0M vs ——EODHD
- Q4 FY20232024-03-27EPS$-0.01 vs $-0.01+46.0%Rev$3.8M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.00 vs $-0.01+71.0%Rev$4.1M vs ——EODHD
- Q2 FY20232023-08-13EPS$-0.01 vs $-0.010.0%Rev$4.0M vs ——EODHD
- Q1 FY20232023-05-14EPS$0.04 vs $-0.01+100.0%Rev$4.1M vs ——EODHD
- Q4 FY20222023-03-28EPS$-0.01 vs $-0.02+50.0%Rev$3.9M vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.01 vs $-0.02+50.0%Rev$3.8M vs ——EODHD
- Q2 FY20222022-08-14EPS$-0.03 vs $-0.030.0%Rev$4.1M vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.02 vs $-0.03+33.3%Rev$4.4M vs ——EODHD
- Q4 FY20212022-03-30EPS$-0.08 vs $-0.02-100.0%Rev$5.0M vs ——EODHD
- Q3 FY20212021-11-14EPS$-0.00 vs $-0.03+98.7%Rev$5.1M vs ——EODHD
- Q2 FY20212021-08-11EPS$-0.03 vs $-0.02-50.0%Rev$5.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-14 | $-0.00 | — | — | — | — | — | EODHD |
| Q4 FY2025 | 2026-03-25 | $-0.00 | — | — | $3.3M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.00 | $0.00 | — | $3.3M | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.00 | $0.00 | — | $3.6M | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.00 | — | — | $3.6M | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.00 | — | — | $3.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.00 | — | — | $3.9M | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.00 | — | — | $4.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.00 | — | — | $4.0M | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-0.01 | $-0.01 | +46.0% | $3.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.00 | $-0.01 | +71.0% | $4.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.01 | $-0.01 | 0.0% | $4.0M | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $0.04 | $-0.01 | +100.0% | $4.1M | — | — | EODHD |
| Q4 FY2022 | 2023-03-28 | $-0.01 | $-0.02 | +50.0% | $3.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.01 | $-0.02 | +50.0% | $3.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.03 | $-0.03 | 0.0% | $4.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.02 | $-0.03 | +33.3% | $4.4M | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.08 | $-0.02 | -100.0% | $5.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.00 | $-0.03 | +98.7% | $5.1M | — | — | EODHD |
| Q2 FY2021 | 2021-08-11 | $-0.03 | $-0.02 | -50.0% | $5.1M | — | — | EODHD |
Source: EODHD. CVSI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks CVSI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.83 | $2.36 | -22.4% | -4.0% | -2.1% |
| Q4 FY2026 | $2.16 | $2.49 | -13.1% | -4.6% | -3.6% |
| Q3 FY2026 | $2.25 | $2.57 | -12.4% | +0.5% | -2.5% |
| Q2 FY2026 | $2.39 | $2.61 | -8.3% | -5.7% | -4.0% |
| Q1 FY2025 | $2.19 | $2.42 | -9.3% | -4.9% | -7.1% |
| Q4 FY2025 | $2.11 | $2.58 | -18.1% | -2.5% | -5.2% |
| Q3 FY2025 | $2.24 | $2.61 | -14.0% | -1.4% | +0.4% |
| Q2 FY2025 | $2.03 | $2.52 | -19.6% | -1.8% | -2.8% |
| Q1 FY2024 | $2.22 | $2.54 | -12.6% | +2.7% | +4.7% |
| Q4 FY2024 | $2.06 | $2.52 | -18.1% | -1.5% | +0.9% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joseph D DowlingCEO8 mo19 callsFormerSample
CEO since 2024 • 7/8 beats (88%) • last guidance cut Q1 FY2026
- Joerg GrasserCFO8 mo19 callsFormerSample
CFO since 2024 • 6/8 beats (75%) • guidance suspended Q2 FY2026
- Douglas Jesse MacKaySr VP Scientific/Regulatory1 yrno recorded callsFormerSample
OTHER since 2020 • 18/24 beats (75%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CVSI.
$ curl https://api.spokenalpha.com/v1/companies/CVSIFAQ
Frequently asked about CVSI
Where can I find CV Sciences, Inc.'s (CVSI) earnings call transcripts?
Spoken Alpha indexes CVSI's earnings call transcripts at https://spokenalpha.com/companies/CVSI. Each call links to attributed speakers and parsed analyst Q&A. CV Sciences, Inc.'s own investor relations page is at https://ir.cvsciences.com/.
When was CV Sciences, Inc.'s most recent earnings call?
CV Sciences, Inc. (CVSI) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
What sector is CVSI in?
CV Sciences, Inc. (CVSI) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).